{"id":2058,"date":"2003-05-01T12:09:00","date_gmt":"2003-05-01T10:09:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure"},"modified":"2003-05-01T12:09:00","modified_gmt":"2003-05-01T10:09:00","slug":"hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure","title":{"rendered":"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure"},"content":{"rendered":"<p>Bei manchen Patienten ist die Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure (ASS) sehr gering, so da\u00df sie dadurch kaum vor thrombotischen Komplikationen gesch\u00fctzt werden. Es gibt Hinweise daf\u00fcr, da\u00df eine Hyperlipid\u00e4mie zu dieser ASS-Resistenz beitragen kann. Aus diesem Grund f\u00fchrten M. Friend et al. aus den USA eine Pilotstudie durch, in die 56 Patienten (72% M\u00e4nner) [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bei manchen Patienten ist die Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure (ASS) sehr gering, so da\u00df sie dadurch kaum vor thrombotischen Komplikationen gesch\u00fctzt werden. Es gibt Hinweise daf\u00fcr, da\u00df eine Hyperlipid\u00e4mie zu dieser ASS-Resistenz beitragen kann. Aus diesem Grund f\u00fchrten M. Friend et al. aus den USA eine Pilotstudie durch, in die 56 Patienten (72% M\u00e4nner) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,77,76,3659,727],"class_list":["post-2058","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-ass","tag-azetylsalizylsaeure","tag-hyperlipidaemie","tag-thrombozytenaggregationshemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2058"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2058\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}